A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas

Trial Profile

A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 31 May 2017

At a glance

  • Drugs NTB 011 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors NantBioScience
  • Most Recent Events

    • 23 May 2017 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
    • 23 May 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.
    • 23 May 2017 Planned initiation date changed from 1 Mar 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top